Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2017

Primary Completion Date

April 1, 2026

Study Completion Date

September 30, 2026

Conditions

Cancer

Interventions

DRUG

Abemaciclib

Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.

Trial Locations (1)

RECRUITING

Dana Farber Cancer Institute, Boston

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER